Drugs / RIBOSE (PYRANOSE)
RIBOSE (PYRANOSE)
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT03133793 | Feb 2018 → Mar 2021 | diastolic heart failure | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01315210 | May 2011 → Oct 2012 | fibromyalgia | RiboCor, Inc. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00329485 | Jun 2006 → Jul 2007 | congestive heart failure | Valen Labs | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01858480 Comparator | Jul → Nov 2013 | congestive heart failure | RiboCor, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RIBOSE (PYRANOSE) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1159662 ↗ |
| Known as | CORvalen | “CORvalen (D-Ribose)” NCT00329485 ↗ |
| Known as | D-Ribose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01315210 ↗ |
| Known as | D-Ribose Oral Powder | “Drug: D-Ribose Oral Powder” NCT03133793 ↗ |
| Modality | Small molecule | — CHEMBL1159662 ↗ |
| Route | Intravenous | “D-ribose administered via peripheral intravenous for 24 hours followed by oral D ribose dosing for 3 months” NCT01858480 ↗ |
| Route | Oral | “D-ribose administered via peripheral intravenous for 24 hours followed by oral D ribose dosing for 3 months” NCT01858480 ↗ |